Aurobindo Pharma Peer Comparison

NSE: AUROPHARMA | BSE: 524804

₹1,672.00

₹-25.70 (-1.51%)

As on 30-Sep-2026IST

Market cap

₹95,887 Cr

Revenue (TTM)

₹34,935 Cr

P/E Ratio

25.8

P/B Ratio

2.5

Div. Yield

0.2 %

Edit

	Aurobindo Pharma	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Lupin
Market cap (₹ Cr)	95,887	1,16,045	1,03,468	1,03,166	93,379
Revenue (₹ Cr)	34,935	28,592	14,738	33,228	29,967
Net Profit (₹ Cr)	3,712.74	4,492.20	2,055.11	3,169.30	5,551.01
Net Margin (%)	10.42	14.92	13.64	9.15	18.23
RoE (%)	10.38	18.78	13.60	8.72	28.32
Price to Earnings	25.83	25.71	50.65	32.02	16.89
Price-To-Book	2.46	4.30	6.15	2.70	3.92

Income Statement (₹ Cr)

	Aurobindo Pharma	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Lupin
Operating Revenue	34,935.29	28,591.70	14,737.88	33,227.90	29,966.58
Total Income	35,624.79	30,111.40	15,061.79	34,650.70	30,442.31
Total Expenditure	27,850.01	21,334.70	10,911.05	28,088.10	20,428.27
EBITDA	7,085.28	7,257.00	3,826.83	5,139.80	9,538.31
Depreciation	1,859.31	1,724.60	893.20	2,119.30	1,529.37
EBIT	5,225.97	5,532.40	2,933.63	3,020.50	8,008.94
Interest	387.88	510.20	578.61	416.30	452.37
Other Income	689.50	1,519.70	323.91	1,422.80	475.73
Exceptional Items	-105.51	-534.80	-129.75	0.00	-557.91
Profit before Tax	5,422.08	6,007.10	2,549.18	4,027.00	7,474.39
Provision for Tax	1,709.34	1,514.90	494.07	857.70	1,923.38
Profit after Tax	3,712.74	4,492.20	2,055.11	3,169.30	5,551.01

	Aurobindo Pharma	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Lupin
Shareholder's Funds	37,890.97	27,111.40	16,300.34	37,891.50	22,448.27
Minority Interest	1.76	-79.70	-24.90	38.90	-22.18
Non-Current Liabilities	2,580.33	7,112.50	5,011.23	3,145.10	3,200.22
Current Liabilities	18,039.01	15,711.90	6,507.25	16,747.40	12,651.24
Total Liabilities	58,196.15	50,672.60	27,754.83	56,576.70	38,146.06

	Aurobindo Pharma	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Lupin
Non-Current Assets	24,040.45	31,677.20	20,274.65	27,204.00	11,888.82
Current Assets	32,708.75	19,906.10	6,954.20	30,179.30	24,027.38
Total Assets	58,196.15	50,672.60	27,754.83	56,576.70	38,146.06
Total Debt*	7,676.20	11,769.50	6,021.78	7,734.10	5,910.20
Net Current Assets	14,669.74	4,194.20	446.95	13,431.90	11,376.14
Contingent Liabilities	1,358.37	989.90	924.77	336.14	1,094.02

	Aurobindo Pharma	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Lupin
Cash From Operating Activities	5,526.37	2,116.60	3,121.29	5,673.70	7,334.50
Cash Flow from Investing Activities	-3,458.61	-8,296.10	-196.42	-6,549.30	-3,864.59
Cash from Financing Activities	-1,269.15	5,806.90	-2,952.69	829.00	-845.87
Net Cash Inflow / Outflow	798.61	-372.60	-27.82	-46.60	2,624.04

	Aurobindo Pharma	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Lupin
ROCE (%)	12.76	21.39	13.24	13.75	28.86
ROE (%)	10.38	18.78	13.60	8.72	28.32
ROA (%)	6.86	10.03	7.36	5.89	16.43
EBIT Margin (%)	14.96	19.35	19.91	9.09	26.73
Net Margin (%)	10.42	14.92	13.64	9.15	18.23
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Aurobindo Pharma	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Lupin
Revenue Growth (%)	9.09	21.11	14.16	-0.87	28.19
EBIT Growth (%)	6.91	-8.99	19.45	-55.06	77.03
Net Profit Growth (%)	8.63	-3.14	8.09	-44.66	49.13
EPS Growth (%)	11.88	4.31	12.27	-43.29	60.86
Book Value Growth (%)	16.04	13.19	13.74	12.99	30.75

	Aurobindo Pharma	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Lupin
Price / Earnings	25.51	23.74	48.14	32.02	15.66
Price / Book Value	2.46	4.30	6.15	2.70	3.92
Dividend Yield (%)	0.24	0.09	0.04	0.65	0.88
EV/EBITDA	13.12	16.62	28.08	20.21	9.44
Market Cap (₹ Cr)	75,689.14	87,643.18	82,801.75	1,04,763.81	1,05,737.27

	Aurobindo Pharma	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Lupin
Debt to Equity	0.02	0.12	0.17	0.00	0.07
Short term debt to equity ratio	0.16	0.16	0.04	0.16	0.18
Current Ratio	1.81	1.27	1.07	1.80	1.90
Quick Ratio	1.15	0.91	0.74	1.35	1.42
Interest Coverage	14.98	12.77	5.41	10.67	17.52

	Aurobindo Pharma	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Lupin
Debtors to sales (%)	20.31	18.94	11.74	30.47	22.04
Asset Turnover	0.65	0.64	0.53	0.62	0.89
Receivable days	33.71	33.55	39.93	103.79	51.23
Inventory Days	59.32	33.80	51.78	79.94	48.93
Payable days	148.20	149.82	111.46	84.78	205.75
Cash Conversion Cycle	-55.17	-82.46	-19.75	98.95	-105.59

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.